Bydureon BCise contains extended-release exenatide and is injected once weekly. Byetta also contains exenatide, but it releases the medicine differently and uses a different injection schedule and device.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | exenatide extended release |
| Medicine class | GLP-1 receptor agonist |
| Forms and strengths | 2 mg/0.85 mL extended-release suspension in a single-dose autoinjector |
Why the extended-release name matters
The US BCise label covers glucose control alongside diet and exercise in adults and children aged 10 years and older with type 2 diabetes. The labeled weekly dose is supplied as a 2 mg/0.85 mL suspension. This formulation is not a dose-for-dose replacement for immediate-release exenatide.
Source: [1]
Preparing the BCise autoinjector
Each BCise autoinjector contains one dose. The medicine is a suspension and needs the preparation described in the instructions supplied with the device. Ask for a demonstration if needed. Instructions for a Byetta pen or an older Bydureon device may not apply to BCise.
Source: [1]
The boxed thyroid warning
Bydureon BCise carries a boxed warning about thyroid C-cell tumors observed in rats; whether this risk applies to humans is unknown. It must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Byetta has different prescribing information and does not carry this boxed warning.
Source: [1]
Other labeled safety considerations
Pancreatitis, serious gastrointestinal effects, kidney problems and immune-mediated thrombocytopenia are important precautions. Prior exenatide-induced immune thrombocytopenia is a contraindication. Injection-site nodules and nausea are commonly reported. Kidney function and the broader treatment plan should be reviewed before use.
Source: [1]
Checking the product supplied
Check that the pack says Bydureon BCise and contains the prescribed autoinjector. Presentations and availability can differ between countries and can change over time. A pharmacist or the manufacturer can answer questions about a particular pack or local supply.
Source: [1]
Questions and answers
Is Bydureon BCise the same as Byetta?
They both contain exenatide, but BCise is extended release and weekly; Byetta is immediate release with a different schedule.
Is the BCise device reusable?
The labeled autoinjector contains one dose and is not a reusable multidose pen.
Does the US label include children?
It includes children aged 10 years and older with type 2 diabetes, subject to the full label and clinical assessment.
Related reading
Sources
Sources checked 1 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026